Moderna, Inc.
Financials
Valuation Metrics
Moderna, Inc.'s Market Cap is $61.11B. At end of 2025 it was $11.56B. Ranked #262 of 3,121 in US market (top 8%), #73 of 1,463 on NASDAQ (top 5%), #16 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $61.11B | US#262/3,121 Sec#16/266 |
| Revenue | $2.23B | US#1,374/3,121 Sec#38/266 |
| Net Income | $-3.15B | US—/3,121 Sec—/266 |
| Total Assets | $10.96B | US#943/3,121 Sec#30/266 |
| Net Assets | $6.76B | US#572/3,121 Sec#22/266 |
| Employees | 4,700 | US#1,259/3,121 Sec#31/266 |
| Value | ||
| P/B | 9.04x | US#2,601/3,121 Sec#191/266 |
| P/S | 27.43x | US#2,882/3,121 Sec#150/266 |
| FCF Yield | -2.00% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -46.61% | US#2,665/3,121 Sec#151/266 |
| ROA | -28.75% | US#2,871/3,121 Sec#150/266 |
| Op. Margin | -149.01% | US#2,759/3,121 Sec#130/266 |
| Revenue Growth | -27.19% | US#2,711/3,121 Sec#157/266 |
| Financial Health | ||
| Debt Ratio | 62.12% | US#685/3,121 Sec#146/266 |
| Total Debt | $1.29B | US#1,407/3,121 Sec#39/266 |
| FCF | $-1.22B | US#2,971/3,121 Sec#261/266 |
| Cash | $1.72B | US#467/3,121 Sec#22/266 |
| Current Ratio | 2.29x | US#1,084/3,121 Sec#215/266 |
| Dividend | ||
| Div. Growth | -60.61% | US—/3,121 Sec—/266 |
| Performance | ||
| 1Y Return | 505.15% | US#8/3,121 Sec#6/266 |
| 1M Return | -11.68% | US#3/3,121 Sec#2/266 |
| From 52W High | -12.82% | US#756/3,121 Sec#53/266 |
| 1Y MDD | -34.16% | US#1,691/3,121 Sec#111/266 |
| Trading | ||
| Volume | 9,191,084 shares | US#88/3,121 Sec#6/266 |
| Trading Value | $1.42B | US#26/3,121 Sec#1/266 |
| Per Share | ||
| EPS | $-7.94 | US—/3,121 Sec—/266 |
| BPS | $17.04 | US#1,412/3,121 Sec#42/266 |
Company Info
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.